The current status of the dopamine hypothesis of schizophrenia
- PMID: 3075131
- DOI: 10.1016/0893-133x(88)90012-7
The current status of the dopamine hypothesis of schizophrenia
Abstract
The dopamine hypothesis of schizophrenia is still almost entirely based on pharmacologic evidence. Even though a disturbed dopamine function has not yet been established beyond doubt in schizophrenia, recent basic research on dopaminergic mechanisms opens up possibilities for the development of more sophisticated pharmacologic tools, capable of discovering subtypes of dopamine receptors, which may turn out to be abnormal in schizophrenia. Such tools may also prove therapeutically useful. Schizophrenia is probably a heterogeneous group of disorders with mixed biopathology. To facilitate the search for nondopaminergic mechanisms of possible pathogenetic importance in subgroups of schizophrenia, a hypothetical model is presented that tries to explain the role of subcortical dopaminergic pathways for mental functions and their interaction with other systems. It is proposed that corticostriatothalamocortical negative feedback loops, also involving the mesencephalic reticular formation, are modulated by mesostriatal dopamine pathways to control a thalamic filter mechanism. The psychotomimetic actions of dopaminergic agents and phencyclidine may be due to interference with these feedback mechanisms.
Similar articles
-
Neurochemical and neural mechanisms of positive and negative symptoms in schizophrenia.Mod Probl Pharmacopsychiatry. 1990;24:124-51. doi: 10.1159/000418015. Mod Probl Pharmacopsychiatry. 1990. PMID: 1970851 Review.
-
Variability and the dopamine hypothesis of schizophrenia.Schizophr Bull. 1983;9(3):325-8. doi: 10.1093/schbul/9.3.325. Schizophr Bull. 1983. PMID: 6622990
-
The dopamine hypothesis of schizophrenia: current status, future prospects.Int Clin Psychopharmacol. 1997 Nov;12(6):297-308. doi: 10.1097/00004850-199711000-00002. Int Clin Psychopharmacol. 1997. PMID: 9547131 Review.
-
Evidence for reduced and dysregulated turnover of dopamine in schizophrenia.Schizophr Bull. 1990;16(4):605-15. doi: 10.1093/schbul/16.4.605. Schizophr Bull. 1990. PMID: 2077638 Review.
-
Psychotogenic drugs as models for schizophrenia.Neuropsychopharmacology. 1988 Sep;1(3):197-9. doi: 10.1016/0893-133x(88)90016-4. Neuropsychopharmacology. 1988. PMID: 2908018 No abstract available.
Cited by
-
Altered striatal functional connectivity in subjects with an at-risk mental state for psychosis.Schizophr Bull. 2014 Jul;40(4):904-13. doi: 10.1093/schbul/sbt093. Epub 2013 Jul 16. Schizophr Bull. 2014. PMID: 23861539 Free PMC article.
-
Toxoplasma gondii infection and behaviour - location, location, location?J Exp Biol. 2013 Jan 1;216(Pt 1):113-9. doi: 10.1242/jeb.074153. J Exp Biol. 2013. PMID: 23225873 Free PMC article. Review.
-
Brain-derived neurotrophic factor controls dopamine D3 receptor expression: implications for neurodevelopmental psychiatric disorders.Neurotox Res. 2002 Nov-Dec;4(7-8):671-678. doi: 10.1080/1029842021000045499. Neurotox Res. 2002. PMID: 12709305
-
Contributions of molecular biology to antipsychotic drug discovery: promises fulfilled or unfulfilled?Dialogues Clin Neurosci. 2006;8(3):303-9. doi: 10.31887/DCNS.2006.8.3/broth. Dialogues Clin Neurosci. 2006. PMID: 17117612 Free PMC article. Review.
-
Schizophrenia: neural mechanisms for novel therapies.Mol Med. 2003 Jan-Feb;9(1-2):3-9. Mol Med. 2003. PMID: 12765334 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical